AU Patent

AU2021300632A1 — Method of achieving HIV viral remission using long-acting antiretroviral agents

Assigned to ViiV Healthcare Co · Expires 2023-02-02 · 3y expired

What this patent protects

A method of achieving HIV viral remission in a patient in need thereof, comprising the steps of: after exposure of the patient to the HIV virus, administering an early antiretroviral therapy (eART) of therapeutically effective amounts of cabotegravir and rilpivirine long-acting a…

USPTO Abstract

A method of achieving HIV viral remission in a patient in need thereof, comprising the steps of: after exposure of the patient to the HIV virus, administering an early antiretroviral therapy (eART) of therapeutically effective amounts of cabotegravir and rilpivirine long-acting antiretrovirals, and after eART suppression of the virus, discontinuing said early antiretroviral therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021300632A1
Jurisdiction
AU
Classification
—
Expires
2023-02-02
Drug substance claim
No
Drug product claim
No
Assignee
ViiV Healthcare Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.